Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Prostate Cancer
100%
Stress Incontinence
61%
Lower Urinary Tract Symptom
59%
Cystectomy
49%
Bladder
46%
Clear Cell Renal Cell Carcinoma
46%
Biopsy Technique
43%
Transitional Cell Carcinoma
40%
Quality of Life
40%
Prostate Specific Antigen
38%
Overactive Bladder
37%
Recurrent Disease
36%
Overall Survival
32%
Interstitial Cystitis
30%
International Prostate Symptom Score
30%
Incontinence
30%
Prostatectomy
29%
Laparoendoscopic Single Site Surgery
28%
Nephroureterectomy
28%
Bladder Cancer
27%
Prostate Hypertrophy
26%
Kidney Metastasis
25%
Nephrectomy
24%
Partial Nephrectomy
23%
Prostate Biopsy
23%
Diseases
23%
Adverse Event
21%
Magnetic Resonance Imaging
20%
Holmium
20%
Tamsulosin
19%
Bladder Outlet Obstruction
19%
Cancer Specific Survival
18%
Prevalence
18%
Transurethral Resection
18%
Nocturia
18%
Obstruction
18%
Malignant Neoplasm
17%
Radical Nephrectomy
17%
Hazard Ratio
17%
Kidney Stone
17%
Propensity Score Matching
17%
Detrusor
16%
Multiparametric Magnetic Resonance Imaging
16%
Retrospective Study
16%
Cystalgia
15%
Gleason Score
15%
Neoplasm
15%
Androgen Deprivation Therapy
15%
Pain
15%
Continence
15%
Pelvic Organ Prolapse
14%
Surgery
13%
Upper Urinary Tract
13%
Tension-Free Vaginal Tape Procedure
13%
Micturition
13%
Urinary Diversion
13%
Biochemical Recurrence
13%
Recurrence Free Survival
13%
Patient Satisfaction
13%
Predictive Factor
12%
Progression Free Survival
12%
PI-RADS
12%
Glomerular Filtration Rate
12%
Urodynamics
12%
Transrectal Ultrasonography
12%
Injection
12%
Body Mass Index
12%
Muscle Contractility
11%
Robot-Assisted Prostatectomy
11%
Radiation Therapy
11%
Pelvis
11%
Odds Ratio
11%
Voiding Dysfunction
11%
Survival Rate
11%
DNA Template
11%
Monotherapy
11%
Urinary System
11%
Enucleation
11%
Seminal Vesicle
11%
Placebo
10%
Adrenalectomy
10%
Peroperative Complication
10%
Bleeding
10%
Urine Incontinence
10%
Prognostic Factor
10%
Postoperative Complication
10%
Extracorporeal
10%
Long-Term Outcome
9%
Contralateral
9%
Surgeon
9%
Proportional Hazards Model
9%
Ureter Obstruction
9%
Kidney Tumour
9%
Chemotherapy
9%
Urologist
9%
Ureter
8%
Median Follow Up
8%
Ureter Stone
8%
Prostate Health Index
8%
Clinical Guideline
8%
Pharmacology, Toxicology and Pharmaceutical Science
Overactive Bladder
93%
Lower Urinary Tract Symptom
46%
Prostate Cancer
45%
Placebo
31%
Tamsulosin
28%
Adverse Event
22%
Mirabegron
22%
Prostate Hypertrophy
20%
Monotherapy
20%
Prostate Specific Antigen
18%
Androgen
15%
Add on Therapy
13%
Bladder Cancer
13%
Solifenacin
12%
Incontinence
12%
Malignant Neoplasm
11%
Syndrome
11%
Stress Incontinence
10%
Obstruction
10%
Transitional Cell Carcinoma
10%
Chemotherapy Regimen
10%
Tolerability
10%
Cholinergic Receptor Blocking Agent
10%
Erectile Dysfunction
10%
Observational Study
9%
Retrospective Study
9%
Urine Incontinence
9%
Botulinum Toxin A
9%
Enuresis
9%
Tolterodine
8%
Kidney Metastasis
8%
Diseases
8%
Overall Survival
8%
Neoplasm
8%
Nocturia
7%
Recurrent Disease
7%
Rat
7%
Bladder Obstruction
7%
Biochemical Recurrence
7%
Potassium Channel
6%
Renal Cell Carcinoma
6%
Propiverine
6%
Large Conductance Calcium Activated Potassium Channel
6%
Progression Free Survival
6%
Xerostomia
6%
Fesoterodine
5%
Castration Resistant Prostate Cancer
5%
Prevalence
5%
Sunitinib
5%
Gemcitabine
5%
Prospective Study
5%
Clostridium Botulinum Type A
5%
Phosphodiesterase V Inhibitor
5%
Oxybutynin
5%
Placebo-Controlled Study
5%
Nursing and Health Professions
Overactive Bladder
59%
Prostate Cancer
27%
Lower Urinary Tract Symptom
27%
Quality of Life
25%
Stress Incontinence
22%
Prevalence
20%
Efficacy
16%
Incontinence
12%
Nocturia
11%
Prostate Specific Antigen
10%
Prostatectomy
9%
Enuresis
9%
Urine Incontinence
9%
Solifenacin
8%
International Prostate Symptom Score
8%
Economic and Social Development
8%
Patient Satisfaction
7%
Syndrome
7%
Suburethral Sling
7%
Bladder Cancer
7%
Tension Free Vaginal Tape
6%
Interstitial Cystitis
6%
Tamsulosin
6%
Cystectomy
6%
Tolterodine
5%
Muscarinic Receptor Blocking Agent
5%
Patient-Reported Outcome
5%
Radiotherapy
5%
Retreatment
5%
Female Patient
5%
Overall Survival
5%
Tension-Free Vaginal Tape Procedure
5%